Fast track status for Novartis MAb Bimagrumab

FDA Grants Novartis Biologic Breakthrough Status

By Dan Stanton

A third Novartis biopharmaceutical has received breakthrough designation status from the FDA allowing ‘fast-track’ development and review without compromising safety, the company says.

GSK Launches $50M ‘Electroceuticals’ Venture Capital Fund

GSK Launches $50M ‘Electroceuticals’ Venture Capital Fund

By Zachary Brennan

GlaxoSmithKline is gambling $50M on a venture capital fund that will invest in 20 projects that pioneer bioelectric drugs and technologies that aim to target individual nerve fibres or specific brain circuits to treat an array of conditions.

Follow us


View more